Imjudo

(Tremelimumab)

Phase 3Monoclonal antibody

Tremelimumab is used to treat certain types of cancer, particularly mesothelioma and hepatocellular carcinoma, by helping the immune system recognize and attack cancer cells. It works by removing the brakes on immune cells so they can fight the cancer more effectively.[1] Imjudo is currently being investigated across 62 indications[3], with its most advanced program in Phase 3.[1]

Imjudo is one of 1134 small molecule programs targeting Head and Neck Carcinoma. It is currently in Phase 3.

Indications

182

Total Trials

Active Trials

1,133

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Head and Neck CarcinomaActive, not recruiting

Pancreatic NeoplasmActive, not recruiting

HIV InfectionActive, not recruiting

Prostate AdenocarcinomaActive, not recruiting

Oral Squamous Cell CarcinomaActive, not recruiting

ToxicityActive, not recruiting

Kidney CancerActive, not recruiting

Lung CancerActive, not recruiting

Esophageal CancerActive, not recruiting

Malignant Pleural MesotheliomaActive, not recruiting

Head and Neck CarcinomaPhase 1/Phase 2

Active, not recruiting

Pancreatic NeoplasmPhase 1

Active, not recruiting

HIV InfectionPhase 2

Active, not recruiting

Prostate AdenocarcinomaPhase 2

Active, not recruiting

Oral Squamous Cell CarcinomaPhase 1

Active, not recruiting

ToxicityPhase 2

Active, not recruiting

Kidney CancerPhase 1

Active, not recruiting

Lung CancerPhase 3

Active, not recruiting

Esophageal CancerPhase 1/Phase 2

Active, not recruiting

Malignant Pleural MesotheliomaPhase 2

Active, not recruiting

Showing 10 of 62 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Imjudo

AstraZeneca

Phase 3

3 2

Tecentriq

Roche

Preclinical

36 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

Bisphosphonate

Amgen

Preclinical

2 9

Lapatinib Plus Capecitabine

GSK

Preclinical

2 10

Aromasin

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Radiotherapy

NCT03410615

Phase 3Active, not recruiting

Hepatocellular Carcinoma

NCT03298451

Phase 3Active, not recruiting

Hepatocellular Carcinoma

NCT05883644

Phase 3Active, not recruiting

Hepatocellular Carcinoma

NCT05557838

Q4 2026

Phase 2Recruiting

Hepatocellular Carcinoma

NCT03482102

Phase 1Recruiting

Tremelimumab

NCT05701488

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma20 trials

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT02519348·433 enrolled

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT03298451·1,324 enrolled

Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

Not yet recruiting·CCenter Eugene Marquis·Phase 2·NCT07122089·80 enrolled

Show 17 more trials

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Recruiting·—·Phase 2·NCT04430452·21 enrolled

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Recruiting· AbbVie logo

AbbVie·Phase 2/3·NCT06109272·660 enrolled

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05883644·111 enrolled

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Active, not recruiting·DDavendra Sohal·Phase 2·NCT05027425·30 enrolled

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Recruiting·MMassachusetts General Hospital·Phase 2·NCT03482102·70 enrolled

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06921785·1,220 enrolled

A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma

Withdrawn·WWeill Medical College of Cornell University·Phase 2·NCT06994299

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03638141·21 enrolled

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02821754·54 enrolled

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Recruiting·TThe University of Hong Kong·Phase 2·NCT05809869·25 enrolled

Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07081633·114 enrolled

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT06526104·32 enrolled

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

Recruiting·TThe University of Hong Kong·Phase 2·NCT04988945·33 enrolled

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Recruiting·AAnwaar Saeed·Phase 2·NCT06698250·40 enrolled

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Withdrawn·—·Phase 1/2·NCT06608940

A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-3)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05301842·760 enrolled

An Open-label, Multi-center Phase IIIb Study of Durvalumab and Tremelimumab as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05557838·214 enrolled

Tremelimumab9 trials

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Completed·CCatherine Shu·Phase 1·NCT03085849·2 enrolled

Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT02040064·27 enrolled

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Completed·LLudwig Institute for Cancer Research·Phase 1·NCT01975831·104 enrolled

Show 6 more trials

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Recruiting·—·Phase 1·NCT05701488·20 enrolled

Durvalumab and Tremelimumab in Resectable HCC

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT05440864·28 enrolled

Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

Completed·AAIO-Studien-gGmbH·Phase 2·NCT03473574·128 enrolled

TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

Active, not recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT04817826·31 enrolled

Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Recruiting·UUniversity of California, San Diego·Phase 1·NCT06710223·20 enrolled

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Completed·LLudwig Institute for Cancer Research·Phase 1/2·NCT02643303·58 enrolled

Bladder Cancer8 trials

Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)

Completed·FFundacion CRIS de Investigación para Vencer el Cáncer·Phase 2·NCT03472274·101 enrolled

Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach

Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT03702179·32 enrolled

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

Withdrawn·—·Phase 2·NCT03150836

Show 5 more trials

TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer

Withdrawn·—·Phase 1·NCT04073160

Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

Terminated·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT03234153·6 enrolled

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT03601455·13 enrolled

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04960709·712 enrolled

Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer

Withdrawn·UUniversity of British Columbia·Phase 1/2·NCT05120622

Lung Cancer7 trials

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT02453282·1,118 enrolled

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Terminated·UUniversity of Wisconsin, Madison·Phase 1·NCT03275597·17 enrolled

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02179671·32 enrolled

Show 4 more trials

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Completed·SSWOG Cancer Research Network··NCT02154490·1,864 enrolled

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT03703297·730 enrolled

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT03164616·1,186 enrolled

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT03373760·67 enrolled

Advanced Solid Tumors6 trials

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02658214·32 enrolled

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Completed·KKyowa Kirin, Inc.·Phase 1·NCT02301130·64 enrolled

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02718911·72 enrolled

Show 3 more trials

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02705482·58 enrolled

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Completed· GSK logo

GSK·Phase 1/2·NCT03693612·26 enrolled

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02261220·380 enrolled

85 more indications

Small Cell Lung Cancer5 trials

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02352948·597 enrolled

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT03043872·987 enrolled

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Unknown status·UUniversity of Sydney·Phase 2·NCT03994393·100 enrolled

Show 2 more trials

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Completed·EEmory University·Phase 2·NCT02701400·18 enrolled

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03923270·25 enrolled

Non-Small Cell Lung Cancer5 trials

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03237377·9 enrolled

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Not yet recruiting·—·Phase 2·NCT07288034·535 enrolled

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02000947·459 enrolled

Show 2 more trials

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Recruiting·GGeorgetown University·Phase 2·NCT04499053·18 enrolled

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT03581487·40 enrolled

Colorectal Cancer4 trials

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT03206073·34 enrolled

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03122509·25 enrolled

Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer

Completed·CCanadian Cancer Trials Group·Phase 2·NCT02870920·180 enrolled

Show 1 more trial

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02754856·24 enrolled

Pancreatic Cancer4 trials

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Recruiting·OOHSU Knight Cancer Institute·Phase 1·NCT04005690·90 enrolled

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02311361·65 enrolled

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Withdrawn·NNYU Langone Health·Phase 1·NCT02868632

Show 1 more trial

Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer

Completed·BBaki Topal·Phase 2·NCT04156087·12 enrolled

Biliary Tract Cancer4 trials

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04238637·50 enrolled

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT06564623·25 enrolled

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05239169·40 enrolled

Show 1 more trial

Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer

Active, not recruiting·SSeoul National University Hospital·Phase 2·NCT03046862·31 enrolled

Prostate Cancer3 trials

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Terminated· Pfizer logo

Pfizer·Phase 1·NCT02616185·91 enrolled

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Completed·CCanadian Cancer Trials Group·Phase 2·NCT02788773·52 enrolled

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03204812·31 enrolled

Liver Cancer3 trials

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Active, not recruiting·—·Phase 1·NCT04605731·25 enrolled

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Recruiting·EEmory University·Phase 2·NCT07174570·39 enrolled

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01853618·61 enrolled

Malignant Mesothelioma3 trials

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT01843374·571 enrolled

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

Unknown status·AAzienda Ospedaliera Universitaria Senese·Phase 2·NCT01655888·29 enrolled

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

Unknown status·AAzienda Ospedaliera Universitaria Senese·Phase 2·NCT01649024·29 enrolled

Esophageal Cancer3 trials

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Completed·LLudwig Institute for Cancer Research·Phase 1/2·NCT02735239·73 enrolled

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02962063·64 enrolled

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Recruiting·AAnwaar Saeed·Phase 1/2·NCT03539822·117 enrolled

Urothelial Cancer3 trials

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT03682068·1,246 enrolled

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT02812420·54 enrolled

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT02516241·1,126 enrolled

Breast Cancer3 trials

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03132467·16 enrolled

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Completed·NNorthwestern University·Phase 2·NCT02536794·30 enrolled

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT02563925·28 enrolled

Renal Cell Carcinoma3 trials

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

Completed·MMoshe Ornstein·Phase 1·NCT02762006·29 enrolled

PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma

Withdrawn·WWashington University School of Medicine·Phase 2·NCT03598816

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

Completed·QQueen Mary University of London·Phase 2·NCT02819596·69 enrolled

Squamous Cell Carcinoma2 trials

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT02499328·340 enrolled

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02319044·267 enrolled

Toxicity2 trials

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03847649·60 enrolled

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown status·CCCTU- Cancer Theme··NCT04107168·1,800 enrolled

Metastatic Colorectal Cancer2 trials

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

Completed·—·Phase 1·NCT03005002·9 enrolled

Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

Completed·NNSABP Foundation Inc·Phase 2·NCT03007407·33 enrolled

Intrahepatic Cholangiocarcinoma2 trials

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Recruiting·MMayo Clinic·Phase 1·NCT06058663·16 enrolled

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Withdrawn·GGeorgetown University·Phase 2·NCT06017297

Chemoradiotherapy2 trials

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Recruiting·MMaximilian Diehn·Phase 3·NCT04585490·48 enrolled

Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

Terminated·TThe Netherlands Cancer Institute·Phase 1·NCT04287894·18 enrolled

Chemotherapy2 trials

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Recruiting·AAHS Cancer Control Alberta·Phase 2·NCT05451043·62 enrolled

Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.

Active, not recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT03704480·106 enrolled

Melanoma2 trials

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Completed·FF. Stephen Hodi, MD·Phase 1·NCT02141542·15 enrolled

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

Completed·AA.J.M. van den Eertwegh·Phase 1·NCT04274816·13 enrolled

Advanced Solid Tumours2 trials

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02586987·58 enrolled

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01938612·269 enrolled

Metastatic Melanoma2 trials

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Completed·—·Phase 1·NCT01103635·25 enrolled

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Completed·—·Phase 1·NCT02639026·53 enrolled

Germ Cell Tumor2 trials

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03158064·30 enrolled

Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors

Terminated·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03081923·36 enrolled

Urothelial Carcinoma2 trials

NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma

Active, not recruiting·AAssociation Pour La Recherche des Thérapeutiques Innovantes en Cancérologie·Phase 1/2·NCT03549715·121 enrolled

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Recruiting·NNoah Hahn, M.D.·Phase 1/2·NCT03317158·55 enrolled

Immunotherapy2 trials

Single cEll pRofiling PErsistaNce To ImmuNothErapy

Recruiting·VVall d'Hebron Institute of Oncology·Phase 2·NCT06680739·60 enrolled

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

Completed·LLudwig Institute for Cancer Research·Phase 1/2·NCT03164772·61 enrolled

Radiotherapy2 trials

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03410615·129 enrolled

Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

Recruiting·—·Phase 2·NCT06999707·45 enrolled

Adenocarcinoma2 trials

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Active, not recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03959293·107 enrolled

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT02340975·114 enrolled

Metastatic Head and Neck Cancer2 trials

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Completed·MMassachusetts General Hospital·Phase 1·NCT03019003·13 enrolled

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02551159·823 enrolled

Malignant Pleural Mesothelioma2 trials

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Terminated·—·Phase 2·NCT03075527·19 enrolled

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Completed·—·Phase 2·NCT02592551·24 enrolled

Advanced Urothelial Cancer1 trial

Improve Checkpoint-blockade Response in Advanced Urothelial Cancer

Completed·TThe Netherlands Cancer Institute·Phase 1/2·NCT03871036·53 enrolled

Maintenance Treatment1 trial

Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)

Withdrawn·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03319316

Metastatic Urothelial Cancer1 trial

Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

Completed·MMatthew Galsky·Phase 2·NCT03557918·26 enrolled

Immunomodulation1 trial

Synergism of Immunomodulation and Tumor Ablation

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03101475·22 enrolled

Primary Peritoneal Cancer1 trial

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Completed·RRoswell Park Cancer Institute·Phase 2·NCT02953457·40 enrolled

Ovarian Cancer1 trial

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Active, not recruiting·NNew Mexico Cancer Research Alliance·Phase 1/2·NCT02571725·50 enrolled

Platinum-resistant1 trial

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT04395079·9 enrolled

Solid Malignancies1 trial

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Active, not recruiting·CCanadian Cancer Trials Group·Phase 1·NCT02537418·153 enrolled

Gynecologic Cancer1 trial

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Terminated·—·Phase 1·NCT03277482·16 enrolled

Patients With Advanced Solid Tumors1 trial

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03509012·105 enrolled

Squamous Cell Cancer1 trial

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03144778·39 enrolled

Metastatic NSCLC1 trial

Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Active, not recruiting·EETOP IBCSG Partners Foundation·Phase 2·NCT03965468·96 enrolled

Myelodysplastic Syndrome1 trial

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02117219·67 enrolled

Pancreatic Adenocarcinoma1 trial

Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Completed·CCanadian Cancer Trials Group·Phase 2·NCT02879318·180 enrolled

ESS1 trial

Himalaya Early Access Program

Approved for marketing· AstraZeneca logo

AstraZeneca··NCT05345678

Mesothelioma1 trial

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02141347·65 enrolled

Thyroid Carcinoma1 trial

Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

Terminated·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT03753919·79 enrolled

Locally Advanced1 trial

Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC

Completed·UUlrich Keilholz·Phase 2·NCT03624231·18 enrolled

Non-squamous NSCLC1 trial

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03057106·301 enrolled

Adjuvant1 trial

Renal Adjuvant MultiPle Arm Randomised Trial

Recruiting·UUniversity College, London·Phase 3·NCT03288532·1,750 enrolled

Advanced NSCLC1 trial

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

Active, not recruiting·SSheba Medical Center·Phase 2·NCT05000710·29 enrolled

Stereotactic Body Radiation Therapy1 trial

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03452332·20 enrolled

Advanced Rare Tumours1 trial

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Completed·CCanadian Cancer Trials Group·Phase 2·NCT02879162·140 enrolled

Head and Neck Cancer1 trial

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02262741·71 enrolled

Relapsed/Refractory1 trial

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02549651·32 enrolled

Metastatic Solid Tumors1 trial

Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors

Withdrawn·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT03982173

Head and Neck Carcinoma1 trial

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Active, not recruiting·—·Phase 1/2·NCT03283605·45 enrolled

Adjuvant Treatment1 trial

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Withdrawn·CCatherine Shu·Phase 2·NCT04625699

Stem Cell Transplant1 trial

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Terminated·LLudwig Institute for Cancer Research·Phase 1·NCT02716805·6 enrolled

Trial1 trial

......SMARTEST Trial......

Completed·UUniversity Health Network, Toronto·Phase 2·NCT05380713·30 enrolled

Endometrial Cancer1 trial

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03015129·80 enrolled

Primary Peritoneal Carcinoma1 trial

Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02485990·24 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Terminated·UUniversity of Washington·Phase 1/2·NCT03522584·6 enrolled

Peritoneal Cancer1 trial

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04034927·61 enrolled

Papilloma1 trial

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Terminated·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT03618134·19 enrolled

Thyroid Cancer1 trial

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03122496·13 enrolled

Elderly Patients1 trial

A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT03975114·460 enrolled

Kidney Cancer1 trial

Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02626130·29 enrolled

Cancer of the Esophagus1 trial

RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

Unknown status·UUniversity of Cologne·Phase 2·NCT04159974·56 enrolled

Fallopian Tube Cancer1 trial

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03026062·100 enrolled

Proton Radiotherapy1 trial

Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

Recruiting·—·Phase 2·NCT06999694·45 enrolled

Efficacy1 trial

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02815995·57 enrolled

Malignant Glioma1 trial

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Completed·NNorthwestern University·Phase 2·NCT02794883·36 enrolled

Solid Tumors1 trial

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Terminated·PPrisma Health-Upstate·Phase 2·NCT02938793·92 enrolled

Adjuvant Therapy1 trial

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

Withdrawn·—·Phase 2·NCT03130764

Neuroendocrine Neoplasm1 trial

Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin

Completed·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT03095274·126 enrolled

Metastatic Cancer1 trial

A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1/2·NCT03212469·54 enrolled

Anatomic Stage IV Breast Cancer AJCC v81 trial

Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03606967·86 enrolled

Solid Tumours1 trial

A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants With Solid Tumours

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07391670·40 enrolled

Unresectable Hepatocellular Carcinoma1 trial

An Observational Study in Patients With Unresectable Hepatocellular Carcinoma (uHCC) Following Treatment With Atezolizumab Plus Bevacizumab (AB) or With Another Approved Immuno-oncology Immune Checkpoint Inhibitor Combination in First-line

Active, not recruiting· Bayer logo

Bayer··NCT06117891·300 enrolled

Solid Tumor, Adult1 trial

Proof of Principle Study Evaluating Single Dose Dual Immune Checkpoint Inhibitors to Increase Intra-tumoral T Cells in Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinomas With ARID1A Mutations: ESR-22-22082

Recruiting·UUniversity of California, Irvine·Phase 1·NCT06824363·34 enrolled

Metastatic Colorectal Carcinoma1 trial

A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02888743·110 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

A Phase IIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment in Metastatic Non-small Cell Lung Cancer Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06008093·103 enrolled

Combined Hepatocellular and Cholangiocarcinoma1 trial

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab (STRIDE) Plus Gemcitabine and Cisplatin (GEMCIS) in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma (cHCC-CCA)

Not yet recruiting·MMehmet Akce·Phase 2·NCT06855225·29 enrolled

Hepatocellular Cancer1 trial

A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03937830·27 enrolled

Advanced Hepatocellular Carcinoma1 trial

Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer With Macrovascular Invasion (HELIO-RT)

Recruiting·NNRG Oncology·Phase 3·NCT07166406·226 enrolled

Hepatocellular Carcinoma Non-resectable1 trial

A Phase II Study of Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04522544·55 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 21, 2022

IMJUDO

BLA BLA761289

Sources

References

[1]
ClinicalTrials.gov — 182 trial records for Tremelimumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tremelimumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tremelimumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761289). U.S. Food & Drug Administration.
[5]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cytotoxic T-Lymphocyte Protein 4 Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca